2-Amino-6-chloropurine-modified polyamidoamine-mediated p53 gene transfection to achieve anti-tumor efficacy

被引:7
作者
Han, Haobo [1 ]
Chen, Wenqi [1 ]
Yang, Jiebing [1 ]
Zhang, Jiayuan [1 ]
Li, Quanshun [1 ]
Yang, Yan [1 ]
机构
[1] Jilin Univ, Sch Life Sci, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130012, Jilin, Peoples R China
基金
中国国家自然科学基金;
关键词
PROSTATE-CANCER CELLS; SIRNA DELIVERY; MUTANT P53; FUNCTIONALIZED POLYAMIDOAMINE; DNA DELIVERY; CYCLE ARREST; THERAPY; PROLIFERATION; DENDRIMERS; APOPTOSIS;
D O I
10.1039/c8nj01870g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The modification of 2-amino-6-chloropurine on polyamidoamine was performed to synthesize a derivative, AP-PAMAM, which was then employed as a carrier for p53 gene delivery to achieve anti-tumor efficacy. Using a human prostate tumor cell line PC-3 as a model, enhanced expression level of p53 gene could be detected by RT-PCR, qPCR and western blotting. Based on the successful p53 gene transfection, an obvious anti-proliferative effect could be obtained, which was identified to be associated with the simultaneous induction of cell apoptosis and cell cycle arrest at the G1 phase. The cell apoptosis was elucidated to be triggered by the activation of the mitochondria-dependent apoptotic signaling pathway. In addition, AP-PAMAM/p53 transfection could restrain the migration of tumor cells as demonstrated by wound healing and Transwell migration assays. Notably, AP-PAMAM-mediated p53 delivery exhibited a stronger inhibitory effect on both cell proliferation and migration than the PAMAM/p53 group. In summary, AP-PAMAM/p53 transfection provided a promising route to achieve the p53-Cbased gene therapy.
引用
收藏
页码:13375 / 13381
页数:7
相关论文
共 13 条
  • [1] Phenylboronic Acid-Modified Polyamidoamine Mediated the Transfection of Polo-Like Kinase-1 siRNA to Achieve an Anti-Tumor Efficacy
    Gong, Gu
    Tang, Xiuhui
    Zhang, Jiayuan
    Liang, Xiao
    Yang, Jiebing
    Li, Quanshun
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2021, 16 : 8037 - 8048
  • [2] Inhibition of cell proliferation and migration through nucleobase-modified polyamidoamine-mediated p53 delivery
    Han, Haobo
    Chen, Wenqi
    Yang, Jiebing
    Liang, Xiao
    Wang, Yudi
    Li, Quanshun
    Yang, Yan
    Li, Kun
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 1297 - 1311
  • [3] The anti-tumor effect of p53 gene-loaded hydroxyapatite nanoparticles in vitro and in vivo
    Zhao, Ruibo
    Yang, Xinyan
    Chen, Cen
    Chen, Kan
    Wang, Shibing
    Xie, Chungang
    Ren, Xiaoyuan
    Kong, Xiangdong
    JOURNAL OF NANOPARTICLE RESEARCH, 2014, 16 (04)
  • [4] Biotinylated transferrin/avidin/biotinylated disulfide containing PEI bioconjugates mediated p53 gene delivery system for tumor targeted transfection
    Zeng, Xuan
    Sun, Yun-Xia
    Qu, Wei
    Zhang, Xian-Zheng
    Zhuo, Ren-Xi
    BIOMATERIALS, 2010, 31 (17) : 4771 - 4780
  • [5] Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane
    Paillas, Salome
    Boudousq, Vincent
    Piron, Berengere
    Kersual, Nathalie
    Bardies, Manuel
    Chouin, Nicolas
    Bascoul-Mollevi, Caroline
    Arnaud, Francois-Xavier
    Pelegrin, Andre
    Navarro-Teulon, Isabelle
    Pouget, Jean-Pierre
    NUCLEAR MEDICINE AND BIOLOGY, 2013, 40 (04) : 471 - 480
  • [6] Lipoic Acid-Modified Oligoethyleneimine-Mediated miR-34a Delivery to Achieve the Anti-Tumor Efficacy
    Huang, Yu
    Wang, Longxiang
    Chen, Yingxuan
    Han, Haobo
    Li, Quanshun
    MOLECULES, 2021, 26 (16):
  • [7] EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-κB/MDM2/p53 Pathway
    Luo, Ke-Wang
    Zhu, Xiao-hong
    Zhao, Ting
    Zhong, Jin
    Gao, Han-chao
    Luo, Xin-Le
    Huang, Wei-Ren
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [8] Expression of Pro-Apoptotic P53 Tumor Suppressor Gene in Pituitary Adenomas: Comparison with Anti-Apoptotic Bcl-2 Oncoprotein
    Tortosa, Francisco
    ARCHIVES OF NEUROSCIENCE, 2019, 6 (01)
  • [9] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Lehmann, Christian
    Friess, Thomas
    Birzele, Fabian
    Kiialainen, Anna
    Dangl, Markus
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [10] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Christian Lehmann
    Thomas Friess
    Fabian Birzele
    Anna Kiialainen
    Markus Dangl
    Journal of Hematology & Oncology, 9